

In the Claims:

Please cancel non-elected claims 1-15, 19-23, and 25-46.

Please amend claims 16-18 and 24 to read as follows:

16. (Amended) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a composition comprising:

(a) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T cell lines or clones is not substantially diminished, wherein the polypeptide comprises the polypeptide set forth in SEQ ID NO:2; and

(b) a physiologically acceptable carrier or excipient;  
and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

17. (Amended) A method for enhancing or inducing an immune response in a patient, comprising administering to a patient the composition according to claim 1.

18. (Amended) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient an immunogenic composition comprising:

(a) a WT1 polypeptide that comprises an immunogenic portion of a native WT1 or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific antibodies and/or T cell lines or clones is not substantially diminished, wherein the polypeptide comprises the polypeptide set forth in SEQ ID NO:2; and

(b) a non-specific immune response enhancer;  
and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

24. (Amended) A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a composition comprising, a WT1 polypeptide comprising the polypeptide set forth in SEQ ID NO:2 and a physiologically acceptable carrier or excipient, thereby stimulating and/or expanding T cells in a mammal.

Please add new claims 47-55 to read as follows:

47. (New) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient a composition comprising:

(a) an isolated polypeptide consisting of an immunogenic portion of a native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the polypeptide consists of no more than amino acids 1-249 of WT1 and wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2; and

(b) a physiologically acceptable carrier or excipient;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

48. (New) The method of claim 47, wherein the polypeptide consists of 4-16 consecutive amino acids of WT1 and comprises at least a portion of SEQ ID NO:2.

49. (New) The method of claim 47, wherein the polypeptide consists of 8-10 consecutive amino acids of WT1 and comprises at least a portion of SEQ ID NO:2.

50. (New) A method for enhancing or inducing an immune response in a human patient, comprising administering to a patient an immunogenic composition comprising:

(a) An isolated polypeptide consisting of an immunogenic portion of a native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or

insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the polypeptide consists of no more than amino acids 1-249 of WT1 and wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2; and

(b) a non-specific immune response enhancer;

and thereby enhancing or inducing an immune response specific for WT1 or a cell expressing WT1 in the human patient.

51. (New) The method of claim 50, wherein the polypeptide consists of 4-16 consecutive amino acids of WT1 and comprises at least a portion of SEQ ID NO:2.

52. (New) The method of claim 50, wherein the polypeptide consists of 8-10 consecutive amino acids of WT1 and comprises at least a portion of SEQ ID NO:2.

53. (New) A method for stimulating and/or expanding T cells in a mammal, comprising administering to a mammal a composition comprising,

a. an isolated polypeptide consisting of an immunogenic portion of a native WT1, or a variant thereof that differs in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the polypeptide consists of no more than amino acids 1-249 of WT1 and wherein said polypeptide comprises the amino acid sequence set forth in SEQ ID NO:2; and

b. a physiologically acceptable carrier or excipient,  
thereby stimulating and/or expanding T cells in a mammal.

54. (New) The method of claim 53, wherein the polypeptide consists of 4-16 consecutive amino acids of WT1 and comprises at least a portion of SEQ ID NO:2.

55. (New) The method of claim 53, wherein the polypeptide consists of 8-10 consecutive amino acids of WT1 and comprises at least a portion of SEQ ID NO:2.